Article
Veterinary Sciences
Da-Eun Lee, Chang-Hoon Nam, Hun-Young Yoon, Kieun Bae, Kyong-Ah Yoon, Jung-Hyun Kim
Summary: This case study presents the clinical outcomes of using TKI therapy in a dog with metastatic and incompletely resected renal cell carcinoma (RCC). The patient showed partial remission of pulmonary nodules after 2 weeks of TKI therapy, and no adverse effects were observed during the treatment period.
FRONTIERS IN VETERINARY SCIENCE
(2023)
Review
Oncology
Estelle Granet-Vaissiere, Felix Lefort, Charlotte Domblides, Mathieu Larroquette, Alain Ravaud, Jean-Christophe Bernhard, Marine Gross-Goupil
Summary: This article summarizes the data on the combination of antiangiogenic and immune checkpoints in the treatment of clear-cell renal-cell carcinoma. The review provides detailed information on the rationale of combining tyrosine kinase inhibitors and immunotherapy, as well as the pre-clinical and clinical experiences that support the synergistic effect between these two therapeutic targets. The article also discusses the different combinations of pembrolizumab-axitinib, pembrolizumab-lenvatinib, and cabozantinib-nivolumab, and how they can guide clinicians in choosing the appropriate treatment.
Article
Oncology
Viktoria Stuehler, Lisa Herrmann, Steffen Rausch, Arnulf Stenzl, Jens Bedke
Summary: First-line immune-based combination therapy and nivolumab after first-line TKI-monotherapy prolong overall survival in metastatic renal cell carcinoma patients in a real-world setting.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Hatice Bolek, Yuksel Urun
Summary: The introduction of TKIs and ICIs has greatly transformed the treatment of advanced RCC, though their efficacy after surgical resection remains controversial. Existing risk stratification methods and biomarkers are not accurate enough. This review provides a comprehensive analysis of key phase 3 RCTs, focusing on the use of TKIs, mTOR inhibitors, and ICIs for adjuvant RCC treatment.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Urology & Nephrology
Robert J. Motzer, Paul Russo, Naomi Haas, Christian Doehn, Frede Donskov, Marine Gross-Goupil, Sergei Varlamov, Evgeny Kopyltsov, Jae Lyun Lee, Ho Yeong Lim, Bohuslav Melichar, Milada Zemanova, Brian Rini, Toni K. Choueirim, Lori Wood, M. Neil Reaume, Arnulf Stenzl, Simon Chowdhury, Ray McDermott, Agnieszka Michael, Miguel Izquierdo, Paola Aimone, Hong Zhang, Cora N. Sternberg
Summary: The PROTECT study found no significant difference in overall survival for patients with locally advanced RCC at high risk of relapse after nephrectomy who received adjuvant therapy with pazopanib or placebo, indicating that pazopanib is not recommended as adjuvant therapy following resection of locally advanced RCC.
Article
Oncology
Yann-Alexandre Vano, Letuan Phan, Gwenaelle Gravis, Iphigenie Korakis, Friederike Schlurmann, Denis Maillet, Mostefa Bennamoun, Nadine Houede, Delphine Topart, Delphine Borchiellini, Philippe Barthelemy, Raffaele Ratta, Thomas Ryckewaert, Ali Hasbini, Sophie Hans, Sheik Emambux, Sandra Cournier, Elena Braychenko, Reza-Thierry Elaidi, Stephane Oudard
Summary: The CABIR study compared the optimal sequence of using CN and NC after frontline VEGFR-TKI in patients with metastatic renal cell carcinoma (mRCC), and found that the NC sequence had a longer progression-free survival (PFS) compared to the CN sequence. The data suggests that cabozantinib may be more effective than nivolumab in the third-line treatment, possibly due to its ability to overcome resistance to PD-1 blockade.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Review
Oncology
Michela Roberto, Andrea Botticelli, Martina Panebianco, Anna Maria Aschelter, Alain Gelibter, Chiara Ciccarese, Mauro Minelli, Marianna Nuti, Daniele Santini, Andrea Laghi, Silverio Tomao, Paolo Marchetti
Summary: In recent years, the therapeutic landscape for metastatic renal cell cancer has expanded with the introduction of various treatment options including molecular targeted agents and immune checkpoint inhibitors. Combining these treatments has shown to improve radiological response, prolong progression-free survival, and overall survival.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Angela Zaccagnino, Bozhena Vynnytska-Myronovska, Michael Stoeckle, Kerstin Junker
Summary: The study found that the tyrosine kinase inhibitor cabozantinib can inhibit the growth of sunitinib-resistant cell lines in metastatic renal cell carcinoma. However, the response to cabozantinib varies among different cell lines, and the MET and AXL expression levels do not affect the responsiveness to cabozantinib.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Jinxin Li, Huimin Sun, Meiling Fu, Zeyuan Zheng, Chunlan Xu, Kunao Yang, Yankuo Liu, Zuodong Xuan, Yang Bai, Jianzhong Zheng, Yue Zhao, Zhiyuan Shi, Chen Shao
Summary: This study demonstrates that high expression of TOPK in RCC promotes PD-L1 expression by activating ERK2 and TGF-beta/Smad pathways. TOPK is also shown to inhibit CD8(+) T cell infiltration and function, promoting immune escape in RCC. Inhibition of TOPK enhances CD8(+) T cell infiltration, activation, anti-PD-L1 therapeutic efficacy, and synergistically enhances anti-RCC immune response.
Review
Oncology
Mathieu Larroquette, Florent Peyraud, Charlotte Domblides, Felix Lefort, Jean-Christophe Bernhard, Alain Ravaud, Marine Gross-Goupil
Summary: Adjuvant systemic therapies for non-metastatic RCC have shown limited effectiveness, leading researchers to explore immune therapy and other alternative strategies to improve patient outcomes and increase cure rates.
CANCER TREATMENT REVIEWS
(2021)
Article
Oncology
Haoran Li, Kamal Kant Sahu, James Brundage, Mallory Benson, Umang Swami, Kenneth M. Boucher, Sumati Gupta, Josiah Hawks, Deepika Sirohi, Neeraj Agarwal, Benjamin L. Maughan
Summary: This phase I trial evaluated the safety and clinical activity of combined therapy with avelumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma. The results demonstrated that this combination therapy is safe and showed positive clinical responses in some patients.
Review
Oncology
Marco Donatello Delcuratolo, Marcello Tucci, Fabio Turco, Rosario Francesco Di Stefano, Antonio Ungaro, Marco Audisio, Alessandro Samuelly, Federica Brusa, Alessandro Audisio, Massimo Di Maio, Giorgio Vittorio Scagliotti, Consuelo Buttigliero
Summary: In the past fifteen years, there has been a significant revolution in the treatment of metastatic renal cell carcinoma (mRCC) due to a better understanding of the biological processes promoting tumor growth and progression. Angiogenesis, as a critical factor in RCC pathogenesis, has led to the development of targeted therapies that interfere with vascular endothelial growth factor and mammalian target of rapamycin pathway. The understanding of the interplay between angiogenesis and immune cells has also led to the approval of dual immune checkpoint inhibitors (ICIs) and ICIs plus tyrosine kinase inhibitors (TKI) combinations as first line treatment, showing overall survival benefit compared to targeted therapies. This article summarizes the activity and biological rationale of ICIs combinations as mRCC first line therapy, as well as reviewing the clinical and biological criteria useful for treatment sequencing, focusing on ICIs combinations resistance mechanisms.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Editorial Material
Oncology
Khalil Saleh, Manal Kordahi, Tony Felefly, Hampig Raphael Kourie, Nadine Khalife
Summary: The optimal sequencing and combination of ICIs to enhance oncologic outcomes for these patients remains a million-dollar question, as it is challenging to strike a delicate balance between utilizing the right window of opportunity to cure the disease and jeopardizing proven therapies for metastatic disease.
Article
Oncology
S. Aeppli, M. Schmaus, T. Eisen, B. Escudier, V Gruenwald, J. Larkin, D. McDermott, J. Oldenburg, C. Porta, B. Rini, M. Schmidinger, C. N. Sternberg, C. Rothermundt, P. M. Putora
Summary: In the first-line treatment of metastatic clear cell renal cell carcinoma, experts recommended various drugs and drug combinations based on different decision criteria and parameters, with significant inter-expert variations observed. This demonstrates how data from randomized trials are implemented differently in daily practice.
Article
Oncology
Yuanquan Yang, Sarah P. Psutka, Anish B. Parikh, Mingjia Li, Katharine Collier, Abdul Miah, Sherry Mori, Megan Hinkley, Scott S. Tykodi, Evan Hall, John A. Thompson, Ming Yin
Summary: The combination of immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) is a new standard of care for the initial treatment of metastatic renal cell carcinoma (mRCC), but its efficacy and toxicity beyond the first-line setting are still uncertain.
Article
Urology & Nephrology
Steffen Lebentrau, Ingmar Wolff, Marie Christine Hempel, Marlene Haccius, Luis A. Kluth, Armin Pycha, Sabine Brookman-May, Till Rasmus Schneider, Thomas Hermanns, Florian A. Distler, Martin Boegemann, Hubert Kuebler, Shahrokh F. Shariat, Maximilian Burger, Matthias May
Summary: The study found that most German-speaking urologists have insufficient knowledge on the association between penile cancer (PeC) and human papilloma virus (HPV). Factors such as autonomous chemotherapy performance for PeC and the number of urological beds in a center had a significant impact on the urologists' understanding of HPV-associated PeC, while other factors like university status or number of PeC patients treated per year did not show significant predictive value.
Article
Urology & Nephrology
F. A. Distler, S. Pahernik, G. Gakis, G. Hutterer, S. Lebentrau, M. Rink, P. Nuhn, S. Brookman-May, M. Burger, C. Gratzke, I. Wolff, M. May
WORLD JOURNAL OF UROLOGY
(2020)
Article
Urology & Nephrology
Ulrike H. Necknig, Ingmar Wolff, Johannes Bruendl, Maximilian C. Kriegmair, David Marghawal, Nina Wagener, Miriam Hegemann, Elisabeth Eder, Christian Wuelfing, Maximilian Burger, Herbert Leyh, Matthias May, Jan Kiesewetter, Marc Weidenbusch
Summary: The study found significant differences among senior physicians in urology regarding surgical skills depending on the time they have held their position, as well as considerable dissatisfaction with the development of leadership skills and preparation for managing tasks. To ensure an adequate availability of senior staff members in the field of urology in the future, it is important to consider their professional needs and address existing shortcomings through education programs within well-coordinated human resources development strategies.
Article
Obstetrics & Gynecology
Bara Barakat, Knut Franke, Sameh Hijazi, Ingmar Wolff, Boris Hadaschik, Christian Rehme
Summary: The objective of the study was to establish a model to predict the presence of female urethral diverticulum (UD) based on symptoms. A prospective CHECK-UD study was conducted on female patients presenting with various symptoms. The combination of LUTS + postmicturition dribble + UTI was found to be the most sensitive in predicting the positive finding of UD.
INTERNATIONAL UROGYNECOLOGY JOURNAL
(2022)
Article
Urology & Nephrology
C. Kaeding, B. Martin, I Wolff
Editorial Material
Oncology
Kay-Patrick Braun, Ingmar Wolff, Steffen Lebentrau, Matthias May
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Pedro Caetano Pinto, Cindy Roennau, Martin Burchardt, Ingmar Wolff
Summary: Kidney cancer and chronic kidney disease have different clinical management strategies, but share closely related cellular and molecular mechanisms, both involving the kidney's response to hypoxia. Fibrosis is a common factor in deteriorating renal function in both conditions.
Letter
Urology & Nephrology
Matthias May, Ingmar Wolff, Sabine D. Brookman-May, Maximilian Burger
SCANDINAVIAN JOURNAL OF UROLOGY
(2022)
Article
Biochemistry & Molecular Biology
Pedro Caetano-Pinto, Nathanil Justian, Maria Dib, Jana Fischer, Maryna Somova, Martin Burchardt, Ingmar Wolff
Summary: The activity of drug transporters in the kidneys and their role in kidney cancer are still not well understood. In this study, different cell lines were used to investigate the activity, expression, and regulatory mechanisms of drug transporters in renal cell carcinoma (RCC). The results showed that RCC cells retained drug transport activity, with P-glycoprotein being localized in the nucleus. The pharmacological inhibition of P-glycoprotein enhanced cisplatin toxicity in non-malignant RPTECs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Obstetrics & Gynecology
Bara Barakat, Ulrich Gauger, Christian Rehme, Boris Hadaschik, Ingmar Wolff, Sameh Hijazi
Summary: This study evaluated the sensitivity and specificity of pelvic floor ultrasound (PFUS) in the diagnosis of female urethral diverticulum (UD) and compared it with voiding cystourethrogram (VCUG). The results showed that PFUS had higher sensitivity and specificity compared to VCUG, suggesting the use of PFUS as part of a non-invasive diagnostic work-up.
INTERNATIONAL UROGYNECOLOGY JOURNAL
(2023)
Article
Oncology
Ingmar Wolff, Martin Burchardt, Christian Gilfrich, Julia Peter, Martin Baunacke, Christian Thomas, Johannes Huber, Rolf Gillitzer, Danijel Sikic, Christian Fiebig, Julie Steinestel, Paola Schifano, Niklas Loebig, Christian Bolenz, Florian A. Distler, Clemens Huettenbrink, Maximilian Janssen, David Schilling, Bara Barakat, Nina N. Harke, Christian Fuhrmann, Andreas Manseck, Robert Wagenhoffer, Ekkehard Geist, Lisa Blair, Jesco Pfitzenmaier, Bettina Reinhardt, Bernd Hoschke, Maximilian Burger, Johannes Bruendl, Marco J. Schnabel, Matthias May
Summary: This study compared the extent of patient's decision regret in patients with prostate cancer undergoing robot-assisted and open surgical approaches, with lower regret reported in the robot-assisted surgery group.
Article
Urology & Nephrology
Steffen Lebentrau, Abdulbaki Yakac, Lukas Lusuardi, Christian Thomas, Semih Sarcan, Maximilian Burger, Axel S. Merseburger, Jens Wiegland, Christain Gilfrich, Ingmar Wolff, Matthias May
Summary: The number of penile cancer cases per hospital in Germany and Austria is low, leading to compromised institutional expertise and inadequate adherence to guidelines. A survey of university hospitals found no significant correlation between case volume and treatment options or quality of care. This highlights the need for nationally organized penile cancer centers.
Article
Oncology
Ingmar Wolff, Martin Burchardt, Julia Peter, Christian Thomas, Danijel Sikic, Christian Fiebig, Soeren Promnitz, Bernd Hoschke, Maximilian Burger, Marco J. Schnabel, Christian Gilfrich, Niklas Loebig, Nina N. Harke, Florian A. Distler, Matthias May
Summary: Certification as a prostate cancer center requires the offer of supportive measures to patients undergoing radical prostatectomy. This study compared the ratings of these measures between certified and non-certified centers. The results showed that the relevance and availability of supportive measures were similar between the two types of centers.
Article
Urology & Nephrology
Abdulbaki Yakac, Steffen Lebentrau, Lukas Lusuardi, Semih Sarcan, Maximilian Burger, Axel S. Merseburger, Jens Wiegland, Christian Gilfrich, Ingmar Wolff, Sascha Ahyai, Matthias May, Christian Thomas
Summary: This study provides insight into the perspectives of urological university department chairs (UUDCs) in Germany and Austria (G + A) on centralization of penile cancer (PeCa) therapy management. Despite the absence of state-regulated centralization, there is a clear focus on PeCa treatment in university hospitals. The majority of UUDCs consider centralization meaningful and feasible, with the establishment of PeCa second-opinion portals being emphasized as important.
UROLOGIA INTERNATIONALIS
(2023)
Review
Urology & Nephrology
Bara Barak, Hazem Othman, Ulrich Gauger, Ingmar Wolff, Boris Hadaschik, Christian Rehme
Summary: This systematic review evaluated the effectiveness of Retzius sparing robot-assisted radical prostatectomy (RS-RARP) compared to standard robot-assisted radical prostatectomy (RARP) in terms of perioperative, functional, and oncological outcomes. The results showed that RS-RARP had a significant advantage in immediate urinary continence recovery, although higher positive surgical margin rates were observed. Erectile function preservation and overall postoperative complication rates were similar between the two techniques.
EUROPEAN UROLOGY FOCUS
(2022)